^
    Back
    Association details:
    Biomarker:CXCL11 elevation
    Cancer:Follicular Lymphoma
    Drug:Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL

    Published date:
    11/01/2018
    Excerpt:
    In the Phase 2 DYNAMO trial of duvelisib monotherapy for relapsed/refractory iNHL....for FL pts between high and low risk subgroups stratified by prognostic indexes...shorter mPFS was associated with higher levels of CXCL11 (9.0 moL, n=39 vs 5.6 moH, n=32) and IL2RA (9.0 moL, n=36 vs 5.6 moH, n=35)...Elevated levels of CXCL11 and IL2RA correlated with shorter mPFS.
    DOI:
    10.1182/blood-2018-99-117903
    Trial ID:
    DYNAMO